Stock PSTX POSEIDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
2.13 USD +3.90% Intraday chart for Poseida Therapeutics, Inc. +5.45% -36.61%
04-08 Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma CI
03-25 Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer MT

Evolution of the average Target Price on Poseida Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

35aa942c4dbb61e3b8c5a31896921.HKEnj4OcxPLiD6ZGc6kaNMloc_Z8_UrIZQt-yKhkBTg.eNt4weyovaqDZ8sLAOVse7MZNZ49q3OgXVQ6q90Cd0Fe7RO7zNiJg4Fb9w~d893b5d40b7861beec685c41d5f9a309

Analyst Recommendations on Poseida Therapeutics, Inc.

Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating MT
HC Wainwright Initiates Poseida Therapeutics With Buy and $15 Price Target MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $11 From $9, Reiterates Overweight Rating MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $9 From $19, Maintains Overweight Rating MT
Cantor Fitzgerald Starts Poseida Therapeutics at Overweight with $24 Price Target MT
POSEIDA THERAPEUTICS : Piper Sandler Adjusts Poseida Therapeutics PT to $19 From $17, Maintains Overweight Rating MT
POSEIDA THERAPEUTICS : BTIG Initiates Poseida Therapeutics at Buy Rating With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.13 USD
Average target price
14 USD
Spread / Average Target
+557.28%
High Price Target
20 USD
Spread / Highest target
+838.97%
Low Price Target
10 USD
Spread / Lowest Target
+369.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Poseida Therapeutics, Inc.

Piper Sandler
HC Wainwright
Cantor Fitzgerald
BTIG

Ratings for Poseida Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PSTX Stock
  4. Consensus Poseida Therapeutics, Inc.